Xenon Pharmaceuticals XENE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $199.16M+39.6% | $142.71M-4.0% | $148.64M+160% | $57.24M-67.4% | ||
| $349.72M-27.8% | $484.19M-1.1% | $489.44M-8.5% | $534.85M+42.2% | ||
| $560.65M-11.7% | $635.26M-1.5% | $644.96M+7.4% | $600.3M+7.4% | ||
| $8.72M-15.1% | $10.28M+6.5% | $9.65M+48.5% | $6.5M+45.5% | ||
| $633.16M-20.7% | $798.14M-17.3% | $964.8M+27.9% | $754.15M+31.8% | ||
| $40.26M+17.6% | $34.22M+31.8% | $25.97M+16.9% | $22.21M+61.9% | ||
| $41.79M+17.4% | $35.59M+30.5% | $27.27M+20.1% | $22.7M+58.5% | ||
| $51.4M+18.9% | $43.24M+17.2% | $36.88M+12.9% | $32.65M+48.6% | ||
| $1.6B+9.7% | $1.46B+1.4% | $1.44B+34.9% | $1.07B+36.0% | ||
| -$1.25B-38.5% | -$899.47M-35.2% | -$665.14M-37.8% | -$482.75M-35.1% | ||
| $581.76M-22.9% | $754.9M-18.6% | $927.92M+28.6% | $721.5M+31.2% | ||
| $633.16M-20.7% | $798.14M-17.3% | $964.8M+27.9% | $754.15M+31.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Xenon Pharmaceuticals cover its short-term obligations?
- Its current ratio is 27.79 — current assets exceed current liabilities.
- Where does Xenon Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.